Back to Agenda
Poster Presentations and Networking Reception
Session Chair(s)
Session Chair Invited, BSN, DDS
Manager, DIA, Switzerland
Poster Presentations and Networking Reception
Speaker(s)
Redaction Impact and Efficiencies Assessed for Optimal Transparency Preparation for the EU Clinical Trial Regulation 536/2014
Manager, Clinical Trial Disclosure & Transparency, CSL Behring, United States
Assessment of Anonymization Methods, Processes, and Challenges for Clinical Information Submissions to Health Canada
Senior Manager, Kinapse Ltd, A Syneos Health Company, United States
Do You Know Your Risk?
Associate Director Clinical Transparency & Trial Disclosure, Regeneron, United Kingdom
Experiences Generating Synthetic Clinical Trial Data
Senior Director, Data Science, Replica Analytics, Canada
Automating Data Anonymization Procedures with Software
, MMS Holdings, United States
Actionable Insights for Plain Language Summary Implementation
Founder and Co-CEO, Krystelis Ltd., India
The Future of Transparency: How Global Regulatory Authorities May Expect Patient and HCP Engagement During the Drug Approval Process
Head, Transparency & Disclosure, Certara, United Kingdom
Have an account?